Vor Biopharma Inc. (NASDAQ:VOR) shares traded 2.87% higher at $4.30 on Wall Street last session.
VOR stock price is now -1.71% away from the 50-day moving average and -22.71% away from the 200-day moving average. The market capitalization of the company currently stands at $155.83M.
With the price target of $18, Wedbush recently initiated with Outperform rating for Vor Biopharma Inc. (NASDAQ: VOR). On April 27, 2022, Goldman recently initiated its ‘Neutral’ rating on the stock quoting a target price of $6, while ‘H.C. Wainwright’ rates the stock as ‘Buy’.
In other news, 5AM Ventures VI, L.P., 10% Owner sold 330,706 shares of the company’s stock on Nov 16. The stock was sold for $5,059,802 at an average price of $15.30. Upon completion of the transaction, the 10% Owner now directly owns 1,766,634 shares in the company, valued at $7.6 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 16, Director PARMAR KUSH sold 330,706 shares of the business’s stock. A total of $5,059,802 was realized by selling the stock at an average price of $15.30. This leaves the insider owning 1,766,634 shares of the company worth $7.6 million. Insiders disposed of 661,412 shares of company stock worth roughly $2.84 million over the past 1 year. A total of 2.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VOR stock. A new stake in Vor Biopharma Inc. shares was purchased by ALLY BRIDGE GROUP (NY) LLC during the first quarter worth $1,097,000. ENSIGN PEAK ADVISORS, INC invested $901,000 in shares of VOR during the first quarter. In the first quarter, DIMENSIONAL FUND ADVISORS LP acquired a new stake in Vor Biopharma Inc. valued at approximately $142,000. TWO SIGMA INVESTMENTS, LP acquired a new stake in VOR for approximately $63,000. SIMPLEX TRADING, LLC purchased a new stake in VOR valued at around $15,000 in the second quarter. In total, there are 79 active investors with 82.20% ownership of the company’s stock.
Vor Biopharma Inc. (NASDAQ: VOR) opened at $4.2000 on Monday. During the past 12 months, Vor Biopharma Inc. has had a low of $3.48 and a high of $18.35. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 12.90, and a quick ratio of 12.90. The fifty day moving average price for VOR is $4.3747 and a two-hundred day moving average price translates $5.5634 for the stock.
The latest earnings results from Vor Biopharma Inc. (NASDAQ: VOR) was released for Jun, 2022.
Vor Biopharma Inc.(VOR) Company Profile
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company’s eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.